$0.77
1.36% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US5288723027
Symbol
LXRX
Sector
Industry

Lexicon Pharmaceuticals, Inc. Stock price

$0.77
-0.03 3.91% 1M
-0.97 55.55% 6M
-0.76 49.45% YTD
-0.69 47.03% 1Y
-3.60 82.30% 3Y
-3.49 81.85% 5Y
-5.45 87.58% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.01 1.45%
ISIN
US5288723027
Symbol
LXRX
Sector
Industry

Key metrics

Market capitalization $279.58m
Enterprise Value $127.08m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 24.30
P/S ratio (TTM) P/S ratio 53.46
P/B ratio (TTM) P/B ratio 1.57
Revenue growth (TTM) Revenue growth 884.75%
Revenue (TTM) Revenue $5.23m
EBIT (operating result TTM) EBIT $-211.12m
Free Cash Flow (TTM) Free Cash Flow $-208.39m
Cash position $258.37m
EPS (TTM) EPS $-0.75
P/E forward negative
P/S forward 25.12
EV/Sales forward 11.42
Short interest 19.35%
Show more

Is Lexicon Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Lexicon Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Lexicon Pharmaceuticals, Inc. forecast:

4x Buy
67%
2x Hold
33%

Analyst Opinions

6 Analysts have issued a Lexicon Pharmaceuticals, Inc. forecast:

Buy
67%
Hold
33%

Financial data from Lexicon Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
5.23 5.23
887% 887%
100%
- Direct Costs 0.89 0.89
68% 68%
17%
4.34 4.34
43,300% 43,300%
83%
- Selling and Administrative Expenses 143 143
47% 47%
2,732%
- Research and Development Expense 72 72
25% 25%
1,377%
-211 -211
36% 36%
-4,026%
- Depreciation and Amortization 0.56 0.56
10% 10%
11%
EBIT (Operating Income) EBIT -211 -211
36% 36%
-4,037%
Net Profit -215 -215
36% 36%
-4,109%

In millions USD.

Don't miss a Thing! We will send you all news about Lexicon Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lexicon Pharmaceuticals, Inc. Stock News

Negative
Reuters
8 days ago
The U.S. Food and Drug Administration declined to approve Lexicon Pharmaceuticals' add-on drug for type 1 diabetes and chronic kidney disease, the company said on Friday.
Neutral
GlobeNewsWire
8 days ago
THE WOODLANDS, Texas, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced it has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Zynquista™ (sotagliflozin) as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and chronic kidney diseas...
Neutral
GlobeNewsWire
about one month ago
Strong Interest in Trial Participation Resulted in Enrollment Exceeding Target by 20 Percent and Completion Ahead of Schedule
More Lexicon Pharmaceuticals, Inc. News

Company Profile

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include XERMELO, Zynquista, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Head office United States
CEO Michael Exton
Employees 285
Founded 1995
Website www.lexpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today